Background: Zinc plays an important role for behavioral and mental function, maintaining the correct functions of intracellular signal transduction, cellular and trans-membrane transport, protein synthesis, and antioxidant system. We investigated both dietary zinc intake and plasma zinc levels and the correlation with depressive symptoms in a large sample of community-dwelling old. Design: One thousand five hundred fourteen older people (aged 60-84 years, 772 women) from the Berlin Aging Study II were included. Zinc intake was assessed by the EPIC Food Frequency Questionnaire. Plasma zinc levels were assessed with atomic-absorption spectrophotometry. Depressive symptoms were assessed with the "Center for Epidemiological Studies Depression Scale" and the "Geriatric Depression Scale." Results: Zinc deficiency in blood plasma was found in 18.7% of participants, and depressive symptoms in 15.7%. Participants with depressive symptoms had lower energy-adjusted zinc intake (median 11.1 vs 11.6 µmol/L; p = .048) and lower plasma zinc levels (median 12.2 vs12.3 mg/ dL; p = .037). Even after adjustment for known predictors of depression, plasma zinc deficiency remained significantly associated with depressive symptoms (odds ratio: 1.490, 95% confidence interval: 1.027-2.164; p = .036). In the multiple logistic regression model stratified by sex, we found that plasma zinc deficiency was strongly associated with a higher risk for depressive symptoms in women (odds ratio: 1.739, 95% confidence interval: 1.068-2.833; p = .026). Conclusions: Plasma zinc deficiency was common in our old study population. An increase in dietary zinc and higher plasma zinc levels may reduce the risk of depressive symptoms. A screening for reduced dietary zinc intake or plasma zinc deficiency might be beneficial in older people at risk of depressive symptoms.
According to the WHO, approximately 350 million people of all ages suffer from depression worldwide, and the prevalence is rising globally (1) . Older people are at particular risk of experiencing depressive symptoms (2) . Depression is associated with a poor quality of life (3) a decreased psychosocial outcome and a reduction in life expectancy (1) . Comparatively, few studies have concentrated on nonpsychological causes of depression such as dietary factors.
Zinc is one of the most important micronutrients in biological systems. It is involved in various aspects of cellular metabolism and maintains the correct functions of a large number of biological and biochemical activities, like intracellular signal transduction, cellular and trans-membrane transport, and protein synthesis (4) . It is required for the catalytic activity of more than 100 enzymes (5) and it plays an important role for behavioral and mental function, antioxidant system, and metabolism (6) . As the body has no particular zinc storage system, a continuous, preferably daily intake of zinc is necessary in order to maintain a steady state (7) .
It is estimated that 25% of the world's population is at risk of zinc deficiency (8) . This is mainly caused by a low intake of foods high in bioavailable zinc, such as red meat, and, as agriculture evolved, a high intake of cereals and therefore phytate which is an indigestible zinc binding ligand. Older people in general have a higher risk of zinc deficiency as studies show that 35-45% of adults aged 60 years or older have inadequate or low zinc intake (9) .
Recent research has shown an association between low dietary intake of zinc and depression in men and in women (10, 11) . Moreover, a small meta-analysis of studies with psychiatric inpatients revealed an impact of low plasma zinc levels on depressive disorders (12) . However, there is a lack of data concerning zinc intake, plasma zinc levels, and depression in the community-dwelling old who are at particular risk of both inadequate zinc intake and depressive symptoms. Also, most studies did not control for known determinants of depression such as poor sleep quality, other micronutrient levels such as vitamin D or B12 which are frequently insufficient in older age and medical conditions such as disease burden, inflammation, hypothyroidism, or cognitive status.
Therefore, the aim of this analysis was to study the association between biomarkers of zinc status and depressive symptoms using both dietary zinc intake as well as plasma zinc levels in a large sample of community-dwelling old women and men taking important confounders into account.
Methods

Berlin Aging Study II
The design of this prospective cohort study on healthy aging including recruitment details has previously been described in detail (13) . The study population consisted of 2,172 (~75% aged 60-84 years and ~25% aged 20-35 years at baseline recruitment) communitydwelling people from the greater metropolitan area of Berlin, Germany. We included 1,514 of the older participants with available data of zinc intake and plasma levels and complete assessment of depressive disorder in this cross-sectional analysis. All participants of the Berlin Aging Study II (BASE-II) gave written informed consent, and the study was approved by the Ethics committee of the Charité-Universitätsmedizin Berlin (approval number EA2/029/09) and registered with the clinical trial registry DRKS (DRKS00009277).
Dietary Zinc Intake
Zinc intake was measured by the validated, self-administered 146-item European Prospective Investigation of Cancer Food Frequency Questionnaire (EPIC-FFQ) (14) , which was completed by all included participants.
The EPIC-FFQ recorded the nutritional intake of the previous year and the frequency of intake was measured using 10 categories ranging from "one time per month or less" to "five times per day or more." It includes questions regarding food intake, such as the seasonal consumption of fruit and vegetables, and frequency of consumption of specific food items (eg, dairy products, meat).
Food groups, protein, carbohydrate, and fat intake were assessed based on portion size (eg, 1 piece, 1 cup, 1 teaspoon per month/week/ day) and calculated in milligrams per day (mg/d). Daily energy and macronutrient intake were determined based on the German food code (Bundeslebensmittelschlüssel 3.01) (15) . Dietary zinc intake was adjusted for energy (2,500 kcal for men and 2,000 kcal for women).
Zinc Levels
Plasma zinc levels were measured by atomic-absorption spectrophotometry (16) and a plasma level ≤11 µmol/L was defined as cut-off for zinc deficiency (8, 17, 18) .
Assessment of Depressive Disorder
The Center for Epidemiological Studies Depression scale (CES-D) is a screening test for depression and depressive disorders. It includes 20 items (eg, feelings of guilt, feelings of hopelessness, loss of appetite, and sleep disturbance) reflecting major dimensions of depression on a 4-point scale ranging from 0 (rare or none of the time) to 3 (most or all of the time). Higher scores indicate more depressive symptoms and a score of 15 or higher is seen as the cut-off point for depressive symptoms (19) .
The Geriatric Depression scale (GDS) allows an early identification of depressive disorders in older people. We used the commonly used short form, including 15 items reflecting major dimensions of depression. Depressive disorder was defined as GDS score equal to or greater than 5 (20) .
To increase sensitivity, we included all participants with a CES-D score of 15 or higher (19) or with a GDS score of 5 or higher (20) in the group of participants with depressive disorders.
We also included 26 cases without pathological findings in the CES-D or GDS but with antidepressant pharmacological treatment, based on the diagnosis of a depressive disorder.
Statistical Analysis
Statistical analyses were carried out using the software package IBM Statistics SPSS 21. Data are given in percent or median with interquartile range (IQR). As all categories were not normally distributed, Mann-Whitney U test was performed to compare mean ranks between groups. Chi-square test was used to compare percentages between groups in relation to categorical variables.
Binary logistic regressions adjusted for multiple potential confounders were performed to calculate odds ratios (ORs) (with 95% confidence intervals [CIs]) for having depressive symptoms. A p-value <.05 was established a priori as level of statistical significance.
Covariables
Sex, age, and body mass index were included as potential confounders in the regression models as well as known potential risk factors for depression like hypothyroidism, plasma levels of vitamin D3 (pmol/L) and vitamin B12 (ng/L), plasma CRP (C-reactive protein) levels (mg/L), cognitive impairment, poor sleep quality, and a morbidity index.
Participants were asked to rate their sleep quality on a scale ranging from 1 (very poor) to 4 (excellent). Very poor and poor sleep quality was established as poor sleep quality. Cognitive impairment was assessed by the Mini-Mental State Examination [MMSE; ≤24 points = cognitive impairment (21)].
Diseases were taken from the medical history recorded by a study physician and determined via laboratory tests (eg, thyroidstimulating hormone/TSH [mU/L] and free-triiodothyronine/FT3 [ng/L] levels in the case of hypothyroidism). The morbidity index was computed based on participant reported and physician-assessed medical diagnosis of diseases representing most of the Charlson comorbidity index categories (22) as described earlier in detail (23) . After calculating the morbidity index, we divided the participants into two groups (0-1 points = no to low morbidity, more than 1 point = medium to high morbidity).
As neither iron (98.94 ± 28.5 µg/dL vs 97.10 ± 33.60 µg/dL ns.) nor ferritin levels (170.3 ± 130,7 µg/L vs 175.5 ± 293.6 µg/L ns.) were significantly different between zinc sufficient and zinc deficient participants, we did not include iron and ferritin levels. Similarly, as magnesium deficiency was found in only 20 and folate deficiency in 38 participants (whereof 8 with depressive symptoms) we did not include these factors either (Table 1) .
Results
One thousand five hundred fourteen participants, 772 women and 742 men, ranging from 60 to 84 years, with a median age of 68 years, were included in this study. Depressive symptoms were seen in 15.7% of the participants. Zinc deficiency in blood plasma (≤11 µmol) was found in 18.7% of the participants and a low zinc intake (under 10.25 mg/d) was seen in 25% of the participants. Table 1 shows the baseline characteristics of the participants with and without any depressive symptoms: Participants with depressive symptoms had a lower energy adjusted zinc intake and a lower plasma zinc level in comparison to participants without depressive symptoms (Figures 1 and 2 ). We moreover found significant differences regarding sex, plasma levels of vitamin B and vitamin D, sleep quality, and the morbidity index between the groups (Table 1) .
After adjusting for the variables that were altered in participants with the risk of depression, plasma zinc deficiency (defined ≤11 µmol/L) remained significantly associated with increased risk of depressive symptoms as shown in Table 2 . Moreover, female sex, poor sleep quality, and higher morbidity were predictive of depressive symptoms.
In a secondary sensitivity analysis, we included only participants who showed depressive symptoms based on both the CES-D and the GDS compared to neither. This lead to larger point estimates for plasma zinc deficiency (OR: 1.651, 95% CI: 1.091-2.497, p = .018) in the risk factor adjusted binary logistic regression.
As the prevalence of depressive symptoms was higher in women (18.5% compared to 12.8% in men, p = .002) and sex specific differences in energy adjusted zinc intake (low intake: 42.4% in women vs 7% in men; p = .001) as well as a significant sex-zinc intake interaction (F = 3.2, p = .024, η 2 = 0.01) were seen, we stratified the analyses by sex to detect possible sex-specific associations between depressive symptoms and risk factors.
In the risk factor adjusted model stratified by sex, the energy adjusted zinc intake was no longer significantly associated with depressive symptoms (data not shown), neither in men nor in women. But as can be seen in Table 3 , plasma zinc deficiency was strongly associated with a higher risk of depressive symptoms in female participants in the logistic regression model.
As anticipated, the morbidity index and the self-reported sleep quality of the female participants had a strong association with depressive symptoms. Other potential predictors such as age, body mass index, vitamin B12, vitamin D, CRP, hypothyroidism, and cognitive impairment showed no significant influence. On the other hand, the model revealed no effect of plasma zinc deficiency on depressive symptoms in men.
In a secondary analysis, we also studied plasma zinc levels as continuous variable and, again found higher levels significantly associated with a lower risk of depressive symptoms in women in the risk factor adjusted model (OR: 0.863, 95% CI: 0.760-0.980, p = .023.)
Discussion
In this study, we explored the association of dietary zinc intake as well as plasma zinc levels with depressive symptoms in a large sample of community-dwelling old. By using the comprehensive data set of the Berlin Aging Study II (13) we were able to adjust for a number of relevant risk factors as possible confounders. Both, low dietary energy adjusted zinc intake and low zinc plasma levels were associated with a higher prevalence of depressive symptoms in older people. Even after adjusting for potential and established risk factors for depression, the association between zinc deficiency and depressive symptoms remained statistically significant. In the multiple risk factors adjusted model, plasma zinc levels showed a stronger relation to depressive symptoms than other potential risk factors for depression like vitamin B12, CRP, and vitamin D and even a closer association with depressive symptoms than well-accepted risk factors such as hypothyroidism. The strong association between morbidity or sleep quality and depressive symptoms has been observed before (24) and was anticipated. Interestingly, in the regression analysis stratified by sex, the overall effect was shown to be due to the strong association in women only. A similar sex-specific effect has been reported once before, however, regarding dietary zinc intake only and not plasma levels (25) . Previous studies showing an association between plasma zinc levels and depression did not stratify data by sex for further analysis.
In general, women are more affected by depressive disorders than men (1) and are more vulnerable for zinc deficiency for dietary reasons, as they often do not consume food rich in bioavailable zinc such as red meat (26) but frequently ingest a diet higher in cereals and legumes that are rich in zinc absorption inhibitors such as phytate (27) . However, although women in our study cohort had a lower dietary zinc intake than men, they exhibited comparable zinc plasma levels. The higher sensitivity to zinc deficiency with regard to depressive symptoms in women might be explained by the similar effects of oestrogen and zinc deficiency on the serotonergic system. Older women have lower levels of oestrogen which has been shown to facilitate serotonin transmission (28) and zinc is believed to play an important role in the up-regulation of serotonin receptors (29) . This might explain the observed difference between women and men regarding the association between zinc and depressive symptoms.
We studied both dietary zinc intake and plasma zinc levels as they were recently categorized as useful biomarkers for zinc intake by the Biomarker of Nutrition for Development (BOND) initiative (30) . Although the energy adjusted zinc intake was lower in participants with depressive symptoms, as has been shown before, it did not remain predictive of depressive symptoms in the risk factor adjusted regression models. Low dietary zinc intake is considered an early indicator of zinc deficiency but might be too short-term to result in manifest depressive disorders, as the biologic half-life of zinc is around 280 days (8) .
However, evaluation of dietary zinc intake remains necessary to identify patients at risk for depressive symptoms as plasma zinc levels are tightly regulated and insensitive to early restriction in dietary zinc intake (31) and only indicate long-term zinc depletion. The early physiologic effects of zinc deficiency are considered to be hidden (31) because intracellular and vesicular zinc states are not easily measurable.
Although we cannot determine causality in our cross-sectional study, a causal relationship between zinc and depressive symptoms, based on the known mechanisms of zinc physiology, is plausible. Zinc maintains behavioral and mental functions by playing a big part in the hippocampus and the amygdala, being a highly concentrated intracellular and extracellular signal factor in these areas. Zinc is released from vesicles in presynaptic glutaminergic neuron terminals and taken up into the neurons through calcium-permeable receptors, such as N-Methyl-d-aspartate receptors. By modulating N-Methyld-aspartate receptors for glutamate, the zinc signaling is involved in synaptic plasticity and cognitive activity (32) . In animal models, zincdeficient rats showed an up-regulation of hippocampal N-Methyl-daspartate receptors (33) and zinc deficient diet caused depressive like behavior in the forced swim test and increased anxiety-like behavior in a light-dark box test (34, 35) . Recent research also indicates a link between zinc levels and serotonin. Zinc deficiency accelerates the interaction of zinc binding G protein-coupled receptor 39 (GPR39) and serotonin binding 5-Hydroxytryptamine 1A (5-HT1A) receptors, generating a GPR39-5HT1A heteroreceptor complex, which is considered to be a depression-causing phenotype (36) . Our study is subject to limitations. It is a cross-sectional study, which means causality cannot be implied. Moreover, as in most epidemiological studies, we only studied self-reported depressive symptoms and a full clinical diagnosis of depression was not available, which would have been superior to self-reported depressive symptoms (37) .
Our results suggest that zinc deficiency is a risk factor for depressive symptoms, at least in older women. In this context, it is worth mentioning that zinc supplementation increased the effect of antidepressant selective serotonin re-uptake inhibitors or imipramine treatment of major depressive disorders in several smaller studies (38, 39) and in a recent, and however small study zinc monotherapy even improved mood in depressed overweight patients (40) .
Conclusions
Both, low dietary energy adjusted zinc intake and low zinc plasma levels showed an association with depressive symptoms in older people. Even after adjusting for potential risk factors, the association between plasma zinc levels and depressive symptoms remained statistically significant which was due to the strong association observed in female participants. This finding implies that in older women at least, who are more vulnerable for depressive disorders as well as zinc deficiency, an increase in dietary zinc and higher plasma zinc levels may reduce the risk of depressive symptoms. A screening for reduced dietary zinc intake should be carried out in older people with depressive symptoms. A routine screening for clinically manifest zinc deficiency might be useful in all depressive patients.
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